



Rydym yn croesawu gohebiaeth yn y Gymraeg ac yn y Saesneg. We welcome correspondence in Welsh or English.

Dyddiad/Date: 9<sup>th</sup> March 2021  
Ein Cyf / Our Ref: 21-B-034

☎ 01639 648363  
✉ FOIA.Requests@wales.nhs.uk

[Redacted]

Corporate Services  
Headquarters  
1 Talbot Gateway  
Baglan  
Port Talbot, SA12 7BR

Dear [Redacted]

I refer to your Freedom of Information Act Request acknowledged by ourselves on 23<sup>rd</sup> February 2021. Your request sought information relating to head & neck cancer.

**We are researching the incidence and treatment of Head & Neck Cancer (H&N), Renal Cancer (RCC) and Colorectal Cancer (CRC). Could you please answer the following questions for patients treated by your Health Board?**

**1. Within your Health Board, how many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents?**

- Carboplatin (monotherapy or in combination with 5-FU) - 10
- Cisplatin (monotherapy or in combination with 5-FU) - 10
- Cetuximab with/without chemotherapy - 0
- Cetuximab with radiotherapy - <5\*
- Pembrolizumab monotherapy - <5\*
- Pembrolizumab with chemotherapy - 0
- Nivolumab - 9
- Docetaxel (monotherapy or in combination with 5-FU) - 0
- Fluorouracil (5FU) - 0
- Radiotherapy only – this information is not held on our Pharmacy systems for these patients
- Other – not applicable

**2. Within your Health Board, how many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:**

- Sunitinib - 7
- Avelumab + Axitinib - <5\*



- Axinitib - <5\*
- Cabozantinib - 15
- Everolimus - 0
- Lenvantinib + Everolimus - <5\*
- Nivolumab - 14
- Nivolumab + Ipilimumab - <5\*
- Pazopanib - 19
- Pembrolizumab + Axitinib - 0
- Sunitinib - As above
- Temsirolimus - 0
- Tivozanib - 9
- Other - 0

**3. Within your Health Board, how many patients have been treated in the past 3 months with the following agents for colorectal cancer [CRC]?**

- Aflibercept - 0
- Bevacizumab - 0
- Cetuximab monotherapy - 0
- Cetuximab in combination with FOLFOX or FOLFIRI - 7
- Panitumumab monotherapy - 0
- Panitumumab in combination with FOLFOX or FOLFIRI - <5\*
- Nivolumab - 0
- Ramucirumab - 0
- Regorafenib - 0
- Sorafenib - 0

\* Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

I hope this information is helpful. If you require anything further please contact us at [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk).

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk).

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2<sup>nd</sup> Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.



Yours sincerely



Pam Wenger  
**Director of Corporate Governance**

